GSK data is no-lose for SRPT no matter what the data is
Either the data from GSK is very good, in which case that further supports the Exon skipping approach, and bolsters SRPT, or the data is bad, which is still good for SRPT because they will have less competition.
Either way it is positive for SRPT.
It is an odd venue for GSK to release the information though. Either it is so good that it can't wait, or so bad they are trying to hide it. In either case, a very odd venue.